Search

Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can be associated with decreases in quality of life (QOL). Bowel-related QOL (BR-QOL) after CRS-HIPEC has not been previously studied. The objectives of the current study were to examine the effect of different types of bowel resection during CRS-HIPEC on overall QOL and BR-QOL., Methods: A prospective cohort study was performed. QOL data were collected using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and CR-29 questionnaires at 3, 6, and 12 months after CRS-HIPEC. Patients were divided into groups that underwent no bowel resection, non-low anterior resection (LAR) bowel resection, LAR, and LAR with stoma. Primary outcomes were global QOL and BR-QOL., Results: Overall, 158 patients were included in this study. Bowel resections were performed in 77% of patients, with 31% undergoing LAR. Global QOL was not significantly different between groups. LAR patients (with and without stoma) had significantly worse BR-QOL, embarrassment, and altered body image, with LAR + stoma patients having the largest impairments in these domains. Trends toward higher levels of impotence and anxiety were also seen in LAR patients. Although global QOL improved over time, impairments in BR-QOL and sexual and social function did not significantly improve over time., Conclusions: Although global QOL after CRS-HIPEC was not affected by the type of bowel resection, the use of LAR and ostomies was associated with clinically meaningful and persistent impairments in BR-QOL and related functional domains. Generic QOL questionnaires may not adequately capture these domains; however, targeted questionnaires in these patients may help improve QOL after CRS-HIPEC.

Background and Objective: The quality of life is advesly affected by type 2 diabetes as a serious metabolic disorder. This study was done to investigate the effect of aerobic training and drug intervention on quality of life in women with type 2 diabetes. Materials and Methods: In this randomized clinical trial study, 52 women with type 2 diabetes divided into four groups including aerobic training with full medicinal doses (group I), aerobic training with half medicinal doses (group II), full medicinal doses without training (group III) and half medicinal doses without training (group IV). Subjects in aerobic training groups participated in 8 weeks training program. Duration of each training session was 45 minutes from the beginning and increased gradually until 105 minutes. Full medicinal doses included Metformin (500 mg) and Glibenclamide (5 mg). Half medicinal doses included Metformin (250 mg) and Glibenclamide (2.5 mg), daily. Subjects without training, did not participate in any physical activities. Quality of life was assessed using SF-36 questionnaire. Data were analyzed using SPSS-18, ANOVA and t dependent tests. Results: There was no significant difference regarding quality of life between groups at pre-test. After the intervention, the quality of life in group I significantly increased (P